We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Workday
WDAY
$41.5B
| $46.4M | 0.07% |
216,053
-1,559
| -0.7% | -$354K |
|
227
Truist Financial
TFC
$63.9B
| $46.3M | 0.07% |
941,192
-12,637
| -1% | -$582K |
|
228
W.W. Grainger
GWW
$64.2B
| $46.3M | 0.07% |
45,867
-296
| -0.6% | -$287K |
|
229
Wabtec
WAB
$49.3B
| $45.9M | 0.07% |
214,923
-13,937
| -6% | -$2.86M |
|
230
Colgate-Palmolive
CL
$74.8B
| $45.8M | 0.07% |
579,469
-40,448
| -7% | -$3.17M |
|
231
Ameriprise Financial
AMP
$47.8B
| $45.6M | 0.07% |
93,046
-1,339
| -1% | -$635K |
|
232
Applovin
APP
$134B
| $45.3M | 0.07% |
67,187
+5,058
| +8% | +$3.19M |
|
233
Rockwell Automation
ROK
$51.1B
| $45.3M | 0.07% |
116,312
+3,061
| +3% | +$1.15M |
|
234
Vaxcyte
PCVX
$7.65B
| $45.2M | 0.07% |
979,765
+256,972
| +36% | +$11.5M |
|
235
Prudential Financial
PRU
$42.6B
| $45.1M | 0.07% |
399,441
-4,285
| -1% | -$459K |
|
236
TSMC
TSM
$1.94T
| $44.3M | 0.07% |
145,834
-24,360
| -14% | -$7.15M |
|
237
Insmed
INSM
$22.4B
| $44.1M | 0.07% |
253,112
+18,490
| +8% | +$3.37M |
|
238
argenx
ARGX
$55.2B
| $44M | 0.07% |
52,347
-14,329
| -21% | -$12.3M |
|
239
CBRE Group
CBRE
$43.3B
| $43.8M | 0.07% |
272,626
-9,054
| -3% | -$1.42M |
|
240
Airbnb
ABNB
$90.8B
| $43.7M | 0.07% |
322,132
-28,832
| -8% | -$3.59M |
|
241
CRH
CRH
$66.6B
| $43.6M | 0.07% |
349,587
+42,366
| +14% | +$5.05M |
|
242
Regency Centers
REG
$14.9B
| $43.5M | 0.07% |
630,726
-2,102
| -0.3% | -$147K |
|
243
IQVIA
IQV
$40.7B
| $43.4M | 0.07% |
192,696
+54,703
| +40% | +$11.9M |
|
244
DoorDash
DASH
$84.3B
| $43M | 0.07% |
189,735
-9,943
| -5% | -$2.33M |
|
245
Edwards Lifesciences
EW
$49.4B
| $42.9M | 0.07% |
503,502
-5,130
| -1% | -$421K |
|
246
PayPal
PYPL
$50.3B
| $42.7M | 0.07% |
730,779
-7,583
| -1% | -$492K |
|
247
Ross Stores
ROST
$80.8B
| $42.6M | 0.07% |
236,647
-401
| -0.2% | -$66.9K |
|
248
Inspire Medical Systems
INSP
$1.47B
| $42.5M | 0.07% |
460,901
+64,561
| +16% | +$6.18M |
|
249
VICI Properties
VICI
$29.9B
| $42.1M | 0.07% |
1,498,085
+124,334
| +9% | +$3.69M |
|
250
Merit Medical Systems
MMSI
$4.82B
| $41.8M | 0.06% |
473,895
-44,768
| -9% | -$3.81M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.